ethyl 2-(2-oxopyridin-1(2H)-yl)acetate | 80056-43-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl 2-(2-oxopyridin-1(2H)-yl)acetate
• 英文别名: ethyl 2-(2-oxo-1,2-dihydropyridin-1-yl)acetate；N-ethoxycarbonylmethyl-2-pyridone；ethyl 2-(2-oxopyridin-1-yl)acetate
• CAS: 80056-43-5
• 化学式: C₉H₁₁NO₃
• mdl: MFCD09260838
• 分子量: 181.191
• InChiKey: IGYRYYXCNGAXIW-UHFFFAOYSA-N

物化性质

• 沸点：
  350.5±25.0 °C(Predicted)
• 密度：
  1.171±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 2-(2-oxopyridin-1(2H)-yl)acetate 在 盐酸 、 水 、 1-羟基苯并三唑 、 lithium hydroxide 作用下， 以 甲醇 、 乙醇 、 正己烷 、 二氯甲烷 为溶剂， 反应 25.33h， 生成 R-1-[2-(2-oxo-2H-pyridin-1-yl)acetamido]-3-methylbutylboronic acid
  参考文献：
  名称：

  Development of peptidomimetic boronates as proteasome inhibitors

  摘要：

  Proteasome inhibition has emerged over the past decade as an effective therapeutic approach for the treatment of hematologic malignancies. It is a multicatalytic complex, whose proteolytic activity relies in three types of subunits: chymotrypsin-like (beta 5), trypsin-like (beta 2) and caspase-like (beta 1). Most important for the development of effective antitumor agents is the inhibition of the beta 5 subunits. In this context, the dipeptide boronate bortezomib (Velcade (R)) represents the first proteasome inhibitor approved by the FDA and the lead compound in drug discovery. This paper describes the synthesis and biological evaluation of a series of conformationally constrained pseudopeptide boronates (1-3) structurally related to bortezomib. The synthesized compounds showed a promising inhibitory profile by blocking primarily the chymotrypsin-like activity of the proteasome with K-i values in submicromolar/micromolar range. These compounds also resulted quite selective since no significant inhibition was recorded in the test against bovine pancreatic alpha-chymotrypsin. The obtained results were rationalized by means of docking experiments based on a model of the crystal structure of bortezomib bound to the yeast 20S proteasome providing essential insights for further optimization of this class of inhibitors. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.03.032
• 作为产物：
  描述：

  2-(苄氧基)吡啶 在 palladium 10% on activated carbon 、 sodium hydride 、 sodium t-butanolate 作用下， 以 甲醇 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 ethyl 2-(2-oxopyridin-1(2H)-yl)acetate
  参考文献：
  名称：

  Development of peptidomimetic boronates as proteasome inhibitors

  摘要：

  Proteasome inhibition has emerged over the past decade as an effective therapeutic approach for the treatment of hematologic malignancies. It is a multicatalytic complex, whose proteolytic activity relies in three types of subunits: chymotrypsin-like (beta 5), trypsin-like (beta 2) and caspase-like (beta 1). Most important for the development of effective antitumor agents is the inhibition of the beta 5 subunits. In this context, the dipeptide boronate bortezomib (Velcade (R)) represents the first proteasome inhibitor approved by the FDA and the lead compound in drug discovery. This paper describes the synthesis and biological evaluation of a series of conformationally constrained pseudopeptide boronates (1-3) structurally related to bortezomib. The synthesized compounds showed a promising inhibitory profile by blocking primarily the chymotrypsin-like activity of the proteasome with K-i values in submicromolar/micromolar range. These compounds also resulted quite selective since no significant inhibition was recorded in the test against bovine pancreatic alpha-chymotrypsin. The obtained results were rationalized by means of docking experiments based on a model of the crystal structure of bortezomib bound to the yeast 20S proteasome providing essential insights for further optimization of this class of inhibitors. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.03.032

文献信息

• Methods and compounds for inhibiting mrp1
  申请人：——

  公开号：US20030100576A1

  公开（公告）日：2003-05-29

  The present invention further relates to a method of inhibiting MRP1 in a mammal which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I).

  本发明还涉及一种抑制哺乳动物中MRP1的方法，包括向需要的哺乳动物施用化合物(I)的有效量。
• 含氮杂环基团取代的酰胺衍生物及其用途
  申请人：广东东阳光药业有限公司

  公开号：CN109761892B

  公开（公告）日：2020-06-05

  本发明公开了含氮杂环基团取代的酰胺衍生物及其用途，具体地，本发明涉及一类新颖的含氮杂环基团基团取代的酰胺衍生物以及包含该类化合物的药物组合物，可用于激活β3‑肾上腺素能受体。本发明还涉及制备这类化合物和药物组合物的方法，以及它们在制备治疗由β3‑肾上腺素能受体激活介导的疾病或病症，特别是膀胱过度活动症的药物中的用途。
• Synthesis and aldose reductase inhibitory activity of substituted 2-oxoquinoline-1-acetic acid derivatives
  作者：Jack DeRuiter、Abram N. Brubaker、William L. Whitmer、James L. Stein

  DOI：10.1021/jm00160a038

  日期：1986.10

  level of aldose reductase inhibitor activity with IC50 values of 0.45-6.0 microM. Modification of the 1-acetic acid moiety by esterification, substitution of an alpha-methyl group, or insertion of an additional methylene unit results in reduced inhibitory potency. Structure-activity data also suggests that both the benzene and 2-oxopyridine rings of 9a-e contribute substantially toward activity and that

  合成了许多包含在醛糖还原酶的几种已知抑制剂中的N-酰基甘氨酸片段的2-氧代喹啉-1-链烷酸，并在大鼠晶状体测定中进行了测试。通过将合适的2-氧代喹啉中间体与卤代酯烷基化，然后将中间体酯水解，可以制备所有目标化合物。在大鼠晶状体测定中，1-乙酸衍生物9a-e显示最高水平的醛糖还原酶抑制剂活性，IC50值为0.45-6.0 microM。通过酯化，α-甲基取代或插入额外的亚甲基单元来修饰1-乙酸部分会导致抑制效力降低。
• [EN] 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE DERIVATIVES AND THEIR USE AS PHD INHIBITORS<br/>[FR] INHIBITEURS 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE DE PHD
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2014160810A1

  公开（公告）日：2014-10-02

  The present invention provides compounds of formula (I) which are useful as inhibitors of PHD, pharmaceutical compositions thereof, methods for treatment of conditions associated with HIF, processes for making the compounds and intermediates thereof.

  本发明提供了公式(I)的化合物，这些化合物可用作PHD的抑制剂，以及与HIF相关疾病的治疗方法，制备这些化合物及其中间体的药物组合物。
• Substituted vinyl pyridine derivative and drugs containing the same
  申请人：SS Pharmaceutical Co., Ltd.

  公开号：US05935977A1

  公开（公告）日：1999-08-10

  The present invention relates to a substituted vinylpyridine derivative represented by the following formula (1): ##STR1## (wherein R.sup.1 represents a hydrogen atom, an alkyl group, etc., R.sup.2 represents an alkyl group; one of R.sup.3 and R.sup.4, which are different from each other, represents a hydrogen atom and the other represents a nitrile group, R.sup.5 represents an aryl group or a heteroaryl group, X represents an oxygen atom, etc., and one of Q.sup.1, Q.sup.2, and Q.sup.3 represents a nitrogen atom and the other two represent CH); a salt of the derivative; and a drug containing the derivative or salt as the active ingredient. Due to strong PDE inhibitory action and TNF-.alpha. production inhibitory action, the derivative, salt, and drug are useful for the prevention and treatment of a wide variety of inflammatory diseases and autoimmune diseases.

  本发明涉及一种由以下式（1）表示的取代乙烯吡啶衍生物：##STR1##（其中R.sup.1代表氢原子、烷基等，R.sup.2代表烷基；R.sup.3和R.sup.4中的一个，二者不同，代表氢原子，另一个代表腈基，R.sup.5代表芳基或杂环芳基，X代表氧原子等，Q.sup.1、Q.sup.2和Q.sup.3中的一个代表氮原子，另外两个代表CH）；该衍生物的盐；以及含有该衍生物或盐作为活性成分的药物。由于具有强烈的PDE抑制作用和TNF-α产生抑制作用，该衍生物、盐和药物对于预防和治疗各种炎症性疾病和自身免疫性疾病非常有用。